Glenmark Pharmaceuticals Ltd on Saturday announced the launch of GLIPIQⓇ (semaglutide) in India for the treatment of Type 2 Diabetes Mellitus (T2DM), positioning it as a more affordable entry into GLP-1 therapy. The company said weekly treatment with the drug will start at ₹325, significantly lowering cost barriers for patients. GLIPIQⓇ has been approved by the Central Drugs Standard Control Organization (CDSCO) after a multicentre, randomised, Phase III clinical trial in India showed favourable safety and efficacy outcomes. The drug is available in both vial and pre-filled pen formats, offering flexibility in dosing and long-term use.
The vial-based formulation, supported by dose-specific syringes, is designed to allow physician-guided dosing and better management in early treatment stages. Glenmark said this approach would help improve access and adherence, especially for patients hesitant to begin injectable therapies due to cost and complexity. The therapy is priced between ₹325 and ₹440 per week. The company has also launched ‘Sankalp’, a patient support programme aimed at improving therapy initiation and long-term adherence.
In Kolkata, the aggressive pricing of GLIPIQⓇ could disrupt the diabetes care segment, where cost remains a key concern. With rising diabetes cases in eastern India, especially in urban centres like Kolkata, affordable GLP-1 therapies are expected to see higher uptake. Healthcare providers in the region noted that the dual-format offering could further support patient compliance and expand access to advanced treatment options.